Insilico Medicine

2 articles

Abstract visualization of AI and DNA merging, representing advancements in regenerative medicine and drug discovery.

AI Advancements Revolutionizing Regenerative Medicine

Insilico Medicine's Rentosertib, an oral small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF), progressed from discovery to a Phase III clinical trial in record time.

Arjun Mehta·July 15, 2026

Scientists in a futuristic lab using AI and holographic displays to advance drug discovery, with glowing DNA strands representing new therapies.

Emerging Tech

Insilico and SK Biopharm Advance AI Drug Discovery

Insilico Medicine's lead drug, INS018_055, reached Phase II trials in 2026, marking it as the first generative AI-designed drug for an AI-discovered target to achieve this milestone.

Arjun Mehta·June 22, 2026